Literature DB >> 4608026

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.

G Mathé, L Schwarzenberg, P Pouillart, R Oldham, R Weiner, C Jasmin, C Rosenfeld, M Hayat, J L Misset, M Musset, M Schneider, J L Amiel, F De Vassal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4608026     DOI： 10.1002/1097-0142(197410)34:4<985::aid-cncr2820340402>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  17 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 2.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  [Successful therapy of chronic myelomonocytic leukemia with vp 16-213 (author's transl)].

Authors:  L Labedzki; H J Illiger
Journal:  Blut       Date:  1979-05

4.  Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia.

Authors:  A T Look; G V Dahl; G Rivera; A M Mauer
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  VM26: phase I and II studies.

Authors:  F R Macbeth
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Preliminary results of chemo-radiotherapy followed or not by active immunotherapy of stage III and IV lymphosarcoma and reticulosarcoma. Correlation of the results with WHO categorisation.

Authors:  J L Misset; G Mathé; M Tubiana; B Caillou; F de Vassal; P Pouillart; M Gil; C Tentas; M Hayat; L Schwarzenberg; C Jasmin; M Delgado; D Machover; P Ribaud; M Musset
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

8.  Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.

Authors:  R E Taylor; T J McElwain; A Barrett; M J Peckham
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Allogeneic bone marrow transplantation as primary therapy for chronic myelomonocytic leukemia.

Authors:  S J Forman; M R O'Donnell; K G Blume; D I Feinstein
Journal:  Blut       Date:  1987-03

10.  Etoposide and cisplatinum in resistant lymphomas.

Authors:  N Tubiana; C Lejeune; N Horchowski; J A Gastaut; M Finaud; D Sainty; G Sebahoun; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.